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Background 
An unlicensed medicine (ULM) is a product which does not have a marketing authorisation from 
the MHRA. ULMs include Specials, food supplements and imported medicines. They have not 
undergone the same regulatory processes as licensed medicines, including rigorous assessment of 
safety and efficacy. How and why prescribers choose to initiate these medicines, pharmacists 
source them and patients use them has never been explored. 
 
Aim and objectives 
• To explore the use of unlicensed medicines across primary and secondary care from the 
perspectives of prescribers, pharmacists and patients 
– To conduct an analysis of guidance documentation designed to support the use of 
unlicensed medicines 
– To describe experiences of prescribing, dispensing and taking ULMs 
– To explore perceptions of risks and benefits associated with ULMs 
– To identify concerns around use of ULMs 
– To discover any perceived improvements to ULM use in the NHS 
 
Methods 
This project incorporated three phases; an analysis of guidance documentation in existence in the 
UK to support the use of unlicensed medicines, qualitative exploration of the use of unlicensed 
medicines using face-to-face semi-structured interviews with prescribers, pharmacists and patients 
sampled across secondary care and focus groups to report the findings of the interviews and 
gather further data on the themes which were identified. 
 
Guideline analysis 
The guideline analysis included documentation from both primary and secondary care which was 
obtained from a combination of database searches and the use of a ‘Call for guidance’ which was 
distributed amongst local and national networks. The analysis incorporated both thematic analysis 
of the content of the guidance documentation and an assessment of quality using the AGREE II 
tool. 
 
Qualitative study 
A grounded theory approach was taken with the qualitative phases, using theoretical sampling to 
identify subsequent participants to interview and using constant comparison to develop themes 
from across the data sample. Participants were drawn from City Hospitals Sunderland NHS 
Foundation Trust, NHS Sunderland Clinical Commissioning Group and the wider NIHR North East 
and North Cumbria Local Clinical Research Network.  
 
Ethical approval was obtained from the NHS West Yorkshire Research Ethics Committee and the 
University of Sunderland Research Ethics Committee. The IRAS reference is 15/YH/0191. This study 
was accepted onto the NIHR Health Services and Delivery portfolio (Reference number: 162518). 
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Results 
Guideline analysis 
With the use of thematic analysis it was revealed that the content varied across the sectors and 
between individual organisations. There were numerous themes which emerged during the 
analysis from which parent themes were elicited (Table 1). It also highlighted a potential lack of 
guidance documentation in primary care, including the community pharmacy setting due to the 
small number of submissions from these settings. The quality of the guidance documentation was 
also very varied according to the AGREE II scoring tool (Figure 1). 
Parent theme Sub-themes 
Responsibility around the use 
of unlicensed medicines 
Understanding the definitions around unlicensed medicines 
Awareness of patients and professionals when using an unlicensed medicine 
Responsibilities of individuals and organisations involved in using unlicensed 
medicines 
References to the guidance and legislation which informed guidance documentation 
Operational issues with using 
unlicensed medicines 
Selecting the pharmaceutical formulation 
Role of the pharmacist and the wider pharmacy team in managing the use of 
unlicensed medicines  
Patient involvement 
Stages of using an unlicensed medicine  
Continuing treatment  
Risk versus benefit 
Evidence to support use of unlicensed medicines  
Place of unlicensed medicines in the treatment of a patient and potential alternatives 
Describing and assessing risk  
Reporting of errors and adverse effects associated with unlicensed medicines 
Controlling the use of 
unlicensed medicines 
Costs associated with unlicensed medicines 
Audit of unlicensed medicines use  
Restricting use of unlicensed medicines  
Organisational decision making surrounding unlicensed medicines 
Table 1: Thematic analysis: generated themes 
 Figure 1: AGREE II domain scores for guidance documentation 
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Qualitative study 
Several themes were identified across the data by healthcare professionals and patients in primary 
and secondary care, including: 
• Healthcare professionals’ awareness of when they were using an ULM and their definition 
of an ULM  
• Perceptions of safety of ULMs was elicited, including the lack of safety and efficacy data 
compared to licensed products and the perceived under-reporting of adverse effects 
• Provision of information and whether patients were likely to be informed about the 
unlicensed status of their medicines, who the person to inform them should be and what 
information patients would want 
• The place of unlicensed medicine use in the clinical management of a patient, including 
whether licensed alternatives were tried first 
• Trust as an important aspect in the use of unlicensed medicines. This was apparent 
throughout the interviews and between all actors 
 
Lack of education and training for healthcare professionals around what an ULM is and the 
associated implications with their use, coupled with a lack of information seems to perpetuate 
problems identified in the use of ULMs. Cost implications associated with ULMs was a strong 
theme among primary care participants, however, many secondary care participants lacked an 
awareness of the associated costs which could lead to under-utilisation of viable alternatives. 
 
Costly and burdensome regulatory processes for medicines licensing were often cited for the use 
of ULMs and seemed to legitimise their routine use in practice. 
 
Discussion 
The lack of marketing authorisation creates many issues in the use of ULMs, including a lack of 
access to information and reduced intelligence around their safety and efficacy. Despite this they 
are generally perceived as safe. The regulatory implications of using ULMs and the potential 
variability between products, does not seem to be well understood. Consideration of how the 
patient will use the medication and the provision of suitable written information seems to be 
inconsistently considered. There is a need for training and the development of mutually agreed 
standards on the use of ULMs to be created to inform a more consistent approach to their use by 
both healthcare professionals and patients.  
 
Whilst pharmacists seem to have a greater knowledge of unlicensed medicines and consider many 
aspects of their use in comparison to their non-pharmacist colleagues, they were often more 
reluctant to inform patients that they were taking an unlicensed medicine and to discuss the 
implications of this. This was in part due to concerns around damaging the patient-prescriber 
relationship and a perception of this being a role for the prescriber. This perception was also 
captured among patient participants. However, patient participants  also expressed that the 
pharmacist who dispenses the medicine should also inform them at the point of giving out the 
prescription. Although patient participants they also acknowledged that this could cause problems 
if the prescriber had not previously informed the patient. 
 
Prescribers often described using pharmacists as a source of information and advice for the use of 
unlicensed medicines, either in the hospital pharmacy department, as part of medicines 
information services, as GP practice pharmacists or local community pharmacists. There was a 
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desire across the settings for prescribers and pharmacists to work more closely together to ensure 
that an unlicensed medicine was the most suitable option for the patient and to ensure that an 
appropriate medicine was supplied.  
 
There seems to be inconsistency in whether patients are informed about the unlicensed status of 
the medicines. The qualitative work found that some patients were not informed, where others 
were very well informed. This is in contrast to the guideline analysis which contained a plethora of 
references to informed consent around initiation of an unlicensed product. However, the lack of 
written information for the patient highlighted in the guideline analysis was also echoed in the 
qualitative work, and so this may be an area for further work. 
 
Patients expressed a desire to be informed of the unlicensed status of their medicine, including 
why the medicine was unlicensed and what the implication of this was for them. It was also 
highlighted that unlicensed medicines are not supplied with a patient information leaflet. A 
standard set of information leaflets for the most commonly used unlicensed medicines as well as a 
generic leaflet on what an unlicensed medicine was, was often cited as a desirable resource for 
healthcare professionals and patients. Patients also wanted to receive information verbally. 
 
A training need was highlighted in the qualitative work and the lack of consistent standards was 
highlighted in the guideline analysis. There is therefore a need for training and the development of 
core standards on the use of ULM in order to inform a more uniform approach to their use. As 
pharmacists become increasingly integrated into general practice and secondary care settings, and 
expand their roles to become prescribers it could be that unlicensed medicines are an area in 
which pharmacists take a specialised role. 
 
There is a lack of transparency around who writes guidance on ULM and on what foundations they 
base their recommendations. Many seemed to be written by pharmacists; the qualitative work 
demonstrated that pharmacists are a source of information frequently utilised by other healthcare 
professionals, therefore it would seem appropriate for them to lead on guidance development. 
However, this raises the question as to whether a lack of multidisciplinary and patient involvement 
perpetuates the lack of awareness of unlicensed medicines outside the pharmacy profession. 
 
There was little documentation from community pharmacy or the primary care sector. It is not 
clear if this is due to a lack of guidance or a lack of submission to the project for analysis. However, 
the lack of references to any sort of guidance in the primary care qualitative work reflects this 
finding and this is an issue that potentially needs to be addressed. It is worth noting that the RPS 
recently updated its guidance on Specials which may improve this. 
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Conclusion 
Unlicensed medicines form part of prescribing practice involving many different healthcare 
professionals and patients. However, their unlicensed status means that many of the tools that are 
traditionally available to support clinical decision making and patient use are lacking. 
 
However, ULMs were often paralleled with licensed medicines by both healthcare professional and 
patient participants, indicating that the licensing status of the product appears to have little impact 
on decision making and processes for use. This is reflected by the fact that prescribers are not 
always aware that they have prescribed an unlicensed product or what the potential implications 
of prescribing them are. Pharmacists appear to have a wider working knowledge than their 
medical and nurse colleagues of ULMs and the potential implications of their use. They are often 
referred to for medicines information and advice. However, despite this, pharmacists seem 
reluctant to discuss the licensing status of medicines with patients and prescribers in the absence 
of a good pharmacist - prescriber relationship. Patients expressed a desire to know the rationale 
behind why an unlicensed medicine was chosen and wanted to have parity of access to 
information to that of licensed medicines. 
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Dissemination of findings 
 
Peer-reviewed publications 
Published: 
Donovan, G., Parkin, L., Wilkes, S (2015) ‘Special unlicensed medicines: what we do and do not 
know about them’ British Journal of General Practice 
 
In preparation for submission: 
Donovan, G., Parkin, L., Brierley-Jones, L., Wilkes, S (draft) ‘Special unlicensed medicines use in the 
UK: A guideline analysis’ Target publication: European Journal of Clinical Pharmacology 
 
Publications planned: 
Methods paper on a grounded theory approach across settings using two independent researchers 
and a combination of interviews and focus groups. Target publication: Health Services Research 
 
Qualitative study exploring the use of unlicensed medicines across primary and secondary care 
from the perspectives of prescribers, pharmacists and patients. Target publication: BMC Health 
Services Research (open access) 
 
Conferences 
Poster presentations 
Unlicensed medicines use in the UK: A systematic review and quality assessment of published 
guidelines, UKCPA Autumn Symposium, November 2015 
 
Abstract submissions 
What is the quality and content of published UK guidelines on the use of unlicensed medicines? 
Society for Academic Primary Care, July 2016 (submitted for poster presentation) 
 
How are unlicensed medicines used in practice by prescribers, pharmacists and patients across 
primary and secondary care? 
Society for Academic Primary Care, July 2016 (submitted for oral presentation) 
 
Exploring the use of unlicensed medicines across primary and secondary care from the 
perspectives of prescribers, pharmacists and patients: A qualitative study 
Royal Pharmaceutical Society Conference, September 2016 
 
Exploring the use of unlicensed medicines across primary and secondary care from the 
perspectives of prescribers, pharmacists and patients: A qualitative study 
UKCPA Autumn Symposium, 2016 (oral presentation) 
 
Study Blog (http://wp.sunderland.ac.uk/emulsionstudy) 
A blog has been established for this project which incorporates both the study progress and 
support for other early careers researchers. This will continue to be updated until the end of 
December 2016. 
 
